The Latest Cardiac and Vascular News
VAPI, India, Nov. 19, 2024 /PRNewswire/ — Meril, a global leader in cutting-edge cardiovascular and structural heart solutions, is renowned for its next-generation transcatheter heart valve technologies. Upholding its commitment to innovation, Meril continues to drive advancements in…
Delivering on commitments, executing ahead of expectations, and raising guidance Innovation driving sustained growth across many franchises: TAVR, PFA, Leadless Pacemakers, Diabetes, Spine, and Neuromodulation GALWAY, Ireland, Nov. 19, 2024 /PRNewswire/ — Medtronic plc (NYSE: MDT) today…
ROME, Nov. 19, 2024 /PRNewswire/ — A comprehensive study led by Professor Dr. Achille Gaspardone was presented at the 2024 TCT Congress which, demonstrated the exceptional efficacy of the Noblestitch™ suture-mediated Patent Foramen Ovale (PFO) closure system in preventing recurrent…
Muvalaplin, an oral, once-daily treatment that inhibits lipoprotein(a) formation via a novel mechanism, achieved positive results in a 12-week Phase 2 study These data were published in the Journal of the American Medical Association (JAMA) and simultaneously presented today at the…
– Acoramidis demonstrated the earliest known time to separation in cardiovascular outcomes in the ATTRibute-CM study (3 months), with statistically significant risk reduction of 36% on All-Cause Mortality (ACM) alone at Month 36 within the Open Label Extension
– sdATEVs maintained sustained patency throughout the six-month study –
Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation MARLBOROUGH, Mass. and CHICAGO, Nov. 16, 2024 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced…
SOUTH SAN FRANCISCO, Calif., Nov. 16, 2024 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced new data from post-hoc analyses of GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure), the Phase 3 cardiovascular outcomes clinical trial of omecamtiv mecarbil were presented at the American Heart Association Scientific Sessions 2024 in Chicago, IL.
CHICAGO–(BUSINESS WIRE)–Vektor Medical, a leader in non-invasive arrhythmia analysis and localization, announced today the presentation of new data showcasing the significant capabilities of vMap, its AI-powered solution for enhancing cardiac arrhythmia treatment. To be presented on November 17 at the American Heart Association (AHA) Scientific Sessions 2024, this data highlights […]
REDWOOD CITY, Calif., Nov. 15, 2024 (GLOBE NEWSWIRE) — Biotricity Inc. (OTCQB: BTCY) (“Biotricity” or the “Company”), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced its financial results for the second quarter of fiscal 2025 year and (unaudited) ended September 30, 2024.
